Our research, both in vivo and in vitro, has demonstrated that M-siTGF-β1 was capable of decrease BLM-induced inflammatory factor production and hydroxyproline content, inhibit the expression of fibrosis-associated molecules, and inhibit EMT formation stimulated by BLM-induced high TGF-β1 expression. Here, TGFB1 is linked to Bloom syndrome.